What Is CJC-1295? A Research Overview

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed with structural modifications to dramatically extend its biological half-life, enabling sustained stimulation of growth hormone (GH) release from the pituitary gland and prolonged elevation of insulin-like growth factor 1 (IGF-1) levels. The original GHRH molecule (also called somatoliberin) has a half-life of only about 7 minutes in the bloodstream due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and other proteases. CJC-1295 was engineered to resist this degradation, resulting in a half-life measured in days rather than minutes.

CJC-1295 exists in two commonly referenced forms. The version "with DAC" (Drug Affinity Complex) incorporates a reactive chemical moiety — maleimidopropionic acid — that forms a covalent bond with serum albumin after injection, extending the peptide's half-life to approximately 6-8 days. The version "without DAC," often called Modified GRF(1-29) or Mod GRF(1-29), has the same amino acid substitutions for DPP-4 resistance but lacks the albumin-binding component, resulting in a shorter half-life of approximately 30 minutes. Both forms are used in research, but they produce different pharmacokinetic profiles.

How Does CJC-1295 Work?

CJC-1295 binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland, mimicking the action of natural GHRH. This receptor activation stimulates a cAMP-dependent signaling cascade that increases GH gene transcription, GH synthesis, and GH secretion. Unlike natural GHRH, which produces brief GH pulses followed by rapid clearance, CJC-1295's extended half-life means the pituitary receives sustained GHRH receptor stimulation.

With the DAC version, this sustained stimulation produces elevated baseline GH levels and amplified GH pulses over the course of several days following a single injection. Research in human subjects showed that a single dose of CJC-1295 with DAC increased mean GH levels 2-10 fold and IGF-1 levels 1.5-3 fold for up to 6 days. Without DAC, the effect is more acute — producing a sharp GH pulse within minutes that dissipates over 1-2 hours, more closely mimicking (though amplifying) natural GHRH pulsatility.

The elevated GH stimulates hepatic IGF-1 production, which mediates downstream anabolic effects including protein synthesis, fat metabolism, and cellular growth and repair. CJC-1295's impact on the GH-IGF-1 axis has made it a central compound in growth hormone research.

Key Research Findings

Study Focus	Model	Key Finding	Year
Pharmacokinetics (with DAC)	Human	Half-life of 5.8-8.1 days; sustained GH/IGF-1 elevation after single dose	2006
GH response (with DAC)	Human	2-10 fold increase in mean GH levels persisting for up to 6 days	2006
IGF-1 elevation (with DAC)	Human	1.5-3 fold IGF-1 increase sustained for 9-11 days after single injection	2006
Dose-response relationship	Human	Dose-dependent increases in GH and IGF-1 with predictable pharmacokinetics	2008
Synergy with GHRP	Human	Combined with ipamorelin, produced synergistic GH release exceeding either alone	2010

Common Research Applications

• Growth hormone augmentation: CJC-1295 is studied as a method to elevate GH and IGF-1 levels in research contexts exploring age-related GH decline (somatopause).
• Body composition research: Investigators examine the effects of sustained GH elevation on fat mass reduction, lean mass preservation, and metabolic rate.
• Combination protocols with ipamorelin: The CJC-1295/ipamorelin combination is one of the most widely studied GH secretagogue stacks, leveraging complementary receptor pathways for synergistic GH release.
• Sleep and recovery research: GH is naturally released in large pulses during deep sleep; studies explore whether CJC-1295 can amplify these sleep-associated GH pulses.
• Comparative pharmacology: CJC-1295 serves as a reference compound for evaluating other GHRH analogs and GH-releasing approaches.

How Does CJC-1295 Compare?

CJC-1295 is most frequently compared to sermorelin, another GHRH analog. While both stimulate the same GHRH receptor, sermorelin has a much shorter half-life (approximately 10-20 minutes) and produces more acute, physiological-pattern GH pulses. CJC-1295 with DAC provides sustained, multi-day GH elevation, while sermorelin requires more frequent dosing. For a detailed comparison, see our CJC-1295 vs. sermorelin comparison. When paired with ipamorelin, CJC-1295 forms a synergistic combination — explore this in our CJC-1295 + ipamorelin research article.

Safety and Considerations

Clinical studies of CJC-1295 have reported generally mild adverse effects, primarily injection site reactions (redness, swelling), transient flushing, and headache. The DAC version, due to its prolonged activity, raises considerations about sustained GH elevation — while this provides research benefits, it also means any adverse effects may persist longer than with shorter-acting compounds. Clinical development of CJC-1295 with DAC was suspended after a participant death in a Phase 2 trial in 2006, though the cause was not conclusively attributed to the compound. CJC-1295 is not approved by any regulatory agency. As with all GH-stimulating agents, theoretical concerns include effects on glucose metabolism and cellular proliferation. This information is for educational and research purposes only and does not constitute medical advice.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC includes a Drug Affinity Complex — a reactive chemical group that covalently bonds to serum albumin after injection, extending the half-life to approximately 6-8 days. CJC-1295 without DAC (Modified GRF 1-29) has the same amino acid backbone with DPP-4-resistant substitutions but no albumin-binding component, giving it a half-life of about 30 minutes. The DAC version produces sustained GH elevation; the non-DAC version produces acute GH pulses.

Why is CJC-1295 combined with ipamorelin rather than used alone?

CJC-1295 acts on the GHRH receptor, while ipamorelin acts on the ghrelin (GHSR-1a) receptor. These are complementary pathways that converge on GH release. When activated simultaneously, they produce synergistic GH output — meaning the combined effect is greater than the sum of the individual effects. This synergy allows researchers to achieve desired GH elevations at lower individual doses.

Does CJC-1295 suppress natural GH production?

Unlike exogenous GH, which can suppress the pituitary's own GH production through negative feedback, CJC-1295 works by stimulating the pituitary to release its own GH stores. Research suggests that GHRH analogs do not cause the same degree of pituitary suppression as exogenous GH administration. However, long-term effects on the GH axis with sustained use have not been comprehensively studied in humans.